КардиАСК Магний is commonly used in clinical settings that involve managing long-term cardiovascular risk, focusing on prophylactic benefit rather than acute symptom relief. This use may assist with managing the risk of acute or recurrent cardiovascular events in established conditions. The medication is relevant for conditions following a previous major vascular incident, such as a heart attack, ischemic stroke, or TIA, and is commonly used for supportive therapy in chronic stable angina or after revascularization procedures.

This therapeutic approach is applied in addressing the high, persistent risk associated with atherosclerosis by helping to manage conditions involving episodic or fluctuating manifestations. The medicine plays a role in managing conditions involving episodic or fluctuating manifestations, which assists with maintaining functional stability. The supportive function of the medicine helps maintain a sense of stability when symptoms are more noticeable. The unique formulation also addresses symptoms related to inflammatory or irritative states, supporting day-to-day comfort for those requiring continuous therapy.

The supportive function of the medicine helps maintain a sense of stability when symptoms are more noticeable.

The Magnesium Hydroxide component assists with managing potential gastrointestinal discomfort, supporting the ability to maintain the required therapeutic regimen.

Quick Fact: Relief for GI Irritation The Magnesium Hydroxide component assists with managing potential gastrointestinal discomfort, supporting the ability to maintain the required therapeutic regimen.

Who Can and Cannot Use КардиАСК?

Eligibility for КардиАСК Магний (Acetylsalicylic Acid + Magnesium Hydroxide) is strictly determined by official regulatory labeling, focusing on pre-existing conditions and specific population groups.

Contraindicated Populations (Must Not Use)

This medicine is contraindicated and must not be used by patients with:

• A known history of hypersensitivity to ASA, salicylates, or other non-steroidal anti-inflammatory drugs (NSAIDs).
• Active peptic ulcer or any form of significant active bleeding or hemorrhagic disorder.
• Severe renal insufficiency, severe hepatic impairment, or severe uncontrolled cardiac insufficiency.
• Women during the third trimester of pregnancy.

Age and Conditional Restrictions

• Pediatric Use: The medicine is not suitable for children under 12 years of age. It is contraindicated in all pediatric patients with suspected viral infections (due to the risk of Reye's Syndrome).
• Pregnancy & Lactation: Use is not recommended while breast-feeding.
• Conditional Use: Caution and supervision are required for populations with a history of gastric or duodenal ulcer, mild to moderate renal impairment, gout, or those with G6PD deficiency.

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for the combination of Acetylsalicylic Acid (ASA) and Magnesium Hydroxide, as stated in government regulatory labeling.

Documented Pharmacodynamic and Pharmacokinetic Interactions

Co-administration with Anticoagulants (such as Warfarin) and other Platelet Aggregation Inhibitors increases the formally recognized risk of hemorrhage due to additive antiplatelet effects. The combination of ASA with Systemic Corticosteroids is also documented to increase the risk of gastrointestinal bleeding. Furthermore, the antiplatelet effect of ASA may be antagonized by certain NSAIDs, such as Ibuprofen, which mandates a specific time separation between doses.

Exposure-Altering Interactions and Restrictions

ASA use is strictly contraindicated with high doses of Methotrexate (ge 15 mg/week) due to the risk of reduced Methotrexate renal clearance and resulting increased toxicity. The Magnesium Hydroxide component may increase the renal clearance of salicylate, potentially leading to a reduction in ASA plasma concentration. Separately, the use of Alcohol (Ethanol) is associated with an increased risk of gastrointestinal blood loss.

Contextual Interaction Constraints

Regulatory information notes that the risk of severe interaction is heightened in certain populations, such as Elderly Subjects and those with Hepatic or Renal Impairment, particularly when combined with anticoagulants. Administration-timing rules must be followed when co-administering interacting NSAIDs.

Irreversible Blockade of Platelet COX-1

The primary mechanism involves Acetylsalicylic Acid (ASA) permanently deactivating the enzyme Cyclooxygenase-1 ( COX-1) found in blood platelets. This occurs through the irreversible covalent acetylation of a serine residue within the enzyme's active site. This permanent blockade prevents the platelets from synthesizing thromboxane A2 ( TXA2), a crucial signaling molecule for TXA2-mediated platelet aggregation. This molecular cascade ultimately leads to a systemic reduction in the capacity for aggregation, a functional change that persists for the entire 7-to-10-day lifespan of the affected platelet.

Component Synergy and Local Gastric pH Modulation

The secondary ingredient, Magnesium Hydroxide, provides a localized complement to the antiplatelet mechanism. It functions as an antacid, engaging in a rapid chemical neutralization of the gastric acid at the site of tablet dissolution. This local buffering action reduces the concentration of unionized acid at the gastric mucosal surface, ensuring the systemic antiplatelet mechanism is delivered without compromising the subsequent absorption required for systemic action.

Administration and Dosing Protocol

КардиАСК is a combination medicine intended for oral administration only. The general principle of its use is defined by a standardized, long-term protocol for supportive antiplatelet therapy. The medication is provided as a film-coated tablet, which must be swallowed whole with a drink of water; the tablet is not to be cut, crushed, or chewed.

The established regimen requires the medicine to be taken once daily to maintain a consistent therapeutic level. Dosing focuses on the Acetylsalicylic Acid (ASA) component, with typical maintenance doses ranging from 75 mg to 150 mg. This usage pattern is specific to chronic application and is not indicated for use as the initial dose during an acute coronary event.

Administration can occur with or without food, though a consistent daily schedule is necessary. If a dose is missed, the standard procedure is to take the next scheduled dose at the regular time without taking two doses together.

Population-Specific Use Constraints

Specific boundaries for use exist based on patient demographics and health status. The medicine is not indicated for use in individuals under 16 years of age. Furthermore, use in patients with severe hepatic impairment is avoided or undertaken with caution. The continuous nature of the therapy requires periodic review by a healthcare provider.

Research Evidence / Overview of Studies

---

Phase III Clinical Trials

Research included the assessment of quality of life endpoints for participants in Phase III trials. Studies investigated whether this treatment was associated with a change in pain perception and the timing of any reported relief in acute flare-ups. One large-scale trial included an analysis of disease activity outcomes over 12 months.

Studies investigated whether the combination was associated with changes in mobility, with outcomes assessed after two weeks. Data from large randomized controlled trials (RCTs) examining low-dose aspirin in cardiovascular risk reduction have demonstrated its role in secondary prevention of events like myocardial infarction and stroke.

---

Mechanism of Action

Studies included analyses of the drug's potential interaction with specific proteins related to inflammation. Acetylsalicylic acid (ASA) is understood to irreversibly inhibit the cyclooxygenase (COX) enzymes, which ultimately interferes with the formation of platelet-aggregating substances, providing its antiplatelet effect. Studies excluded participants with an active viral infection.

---

Comparative Studies

Research has compared this approach to older methods in cardiovascular prevention. Studies have also examined whether the progression of the condition may be influenced by this treatment. Studies explored whether combining the treatment with a specific diet plan was associated with differences in observed study endpoints, particularly related to lipid profiles.

---

Safety and Tolerability Profile

The most frequently reported adverse events in clinical studies were classified as mild and short-lived in study records, often related to gastrointestinal issues. Research has included participants with mild liver impairment, but aspirin is generally avoided in severe liver disease. Major safety concerns, such as bleeding risk, are continuously evaluated against the potential clinical benefits.

Key Studies & References Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force

Common questions about КардиАСК (FAQ)

Q: Is КардиАСК a blood pressure lowering medicine?

According to official regulatory documents, КардиАСК is classified as an antiplatelet agent, and its primary function is to help prevent blood clots. It is not indicated as a primary blood pressure-lowering medication. While some studies have examined its potential effect on blood pressure, its defined primary role is associated with modifying platelet activity to help prevent blood clots.

Q: What kind of pain is КардиАСК typically used for?

The purpose of this medicine is specifically to provide cardiovascular protection and reduce the risk of blood clot formation. It is not intended for use as a typical pain reliever or fever reducer, even though its active ingredient (Acetylsalicylic Acid) is common in those medicines. The dosing protocol defined in official prescribing information is specific to chronic antiplatelet therapy.

Q: How does the low dose of КардиАСК relate to its use for the heart?

The low dosage is used because it is believed to specifically target and irreversibly inhibit the COX-1 enzyme in blood platelets, which is the key mechanism for its anti-clotting effect. This dosage range is generally used to achieve an antiplatelet effect for chronic, long-term use while helping to limit other systemic effects.

Q: Are headaches or dizziness listed as possible side effects of КардиАСК?

Official information does not typically list simple headaches as a common adverse reaction of this medicine. However, dizziness is sometimes mentioned in official sources as a symptom that may occur in conjunction with severe allergic reactions or in situations related to higher concentrations of the medicine.

Q: Are there common supplements or vitamins that may interact with КардиАСК?

Regulatory documents note that the active ingredient, Acetylsalicylic Acid, can potentially interfere with the action of Vitamin K. Furthermore, some common herbal remedies and supplements, such as those with noted blood-thinning properties like Ginkgo biloba, are documented to potentially increase the risk of bleeding when combined with this medicine.

Q: Is it necessary to temporarily stop КардиАСК before a dental procedure?

Guidelines generally state that patients on low-dose antiplatelet therapy should not interrupt their medicine for routine dental extractions or minor oral surgery. This is because the risk of a serious blood clot event from stopping the drug is usually considered higher than the bleeding risk from continuing it. Guidance emphasizes that any decision regarding temporary interruption of therapy should involve the prescribing healthcare professional.

Q: How is the drug classified in terms of risk during surgery?

The risk associated with this medicine during surgery is managed through a personalized assessment before any invasive procedure. Official advisories suggest that the risk of stopping the therapy for minor procedures may often outweigh the bleeding risk of continuing it. The final decision for the perioperative period depends on the specific procedure and the patient’s condition.

Q: Is the purpose of taking КардиАСК mainly preventative?

The purpose of this medication is preventative in nature, aiming to reduce the risk of serious cardiovascular events. Official documentation indicates a demonstrated benefit in secondary prevention, which involves preventing events after a previous heart event or stroke. Its use for primary prevention (preventing a first event) requires an individualized risk assessment.

Q: What is the usual non-clinical expectation for how long patients take КардиАСК?

Because this medicine is intended for managing a chronic condition, the treatment protocol is generally described as a continuous, daily regimen. This long-term protocol suggests that patients may take the medicine for many years or indefinitely. The duration of therapy is always subject to periodic review by a healthcare provider.

Q: What is the difference between КардиАСК and standard over-the-counter aspirin?

The key difference is that this is a combination medicine containing both the active ingredient, Acetylsalicylic Acid, and Magnesium Hydroxide. The Magnesium Hydroxide is included as an antacid that provides localized pH modulation, which may be a consideration for stomach protection. This feature is often absent in standard single-component aspirin products.

Q: Is КардиАСК the same as other antiplatelet drugs?

This medicine is classified pharmacologically as an antiplatelet agent, meaning it modifies the action of blood platelets to help prevent clotting. However, its composition as a fixed-dose combination of two active components—Acetylsalicylic Acid and Magnesium Hydroxide—distinguishes it from other antiplatelet drugs that may contain only one ingredient.

Q: What general safety concerns are listed for long-term use of КардиАСК?

Regulatory safety information emphasizes the necessity of continuous monitoring for certain risks associated with long-term use. Key concerns noted include the potential for developing gastrointestinal ulcers, severe stomach bleeding, and the general risk of hemorrhage (bleeding).

Q: Can a patient stop taking КардиАСК if they feel their condition has improved?

Official guidance advises against discontinuing the antiplatelet medicine without consulting a healthcare professional. Abruptly stopping the therapy may increase the risk of serious thrombotic events, such as heart attack or stroke, due to the drug's role in preventing blood clot formation.

Q: Does the medicine help with cholesterol levels?

This medication is not classified as a cholesterol- or lipid-lowering agent. Its defined pharmacological action is solely antiplatelet, focused on modifying blood clotting action. While cholesterol levels are an important part of overall cardiovascular risk management, that is the role of other types of medicine.

Q: Is КардиАСК an immediate-release or modified-release tablet?

This medicine is provided as a film-coated tablet that is generally described in official sources as having a delayed release (a type of modified release) formulation. This design protects the active ingredient from stomach acid and ensures that it dissolves later in the digestive tract.

Storage and Disposal Requirements

This medication must be stored according to regulatory requirements to maintain the stability of the active ingredient, Acetylsalicylic Acid (ASA).

Condition	Requirement
Temperature	Store at room temperature, typically 15^circC to 30^circC (59^circF to 86^circF).
Protection	Keep the container tightly closed and protect from excessive heat and moisture; do not store in the bathroom.
Stability Warning	Do not use the tablets if they develop a strong vinegar-like smell, which indicates decomposition.
Child Safety	Must be stored out of sight and reach of children.

For disposal, unused or expired tablets must not be simply thrown in the trash or down the drain. Follow official local drug take-back programs or consult a pharmacist for instructions on how to properly discard the medicine.